TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT01986413

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: pressure controlled ventilation BIPAP ST
Description: spontaneous timed pressure controled bilevel ventilation

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: volume assured pressure support IVAPS
Description: intelligent volume assured Pressure Support

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: NIV
Description: Patients with COPD and chronic hypercapnic respiratory failure will spent two nights on NIV, one with spontaneous timed pressure controlled bilevel ventilation (BiPAP ST) and one with the advanced mode of intelligent volume assured pressure support (IVAPS). Patients will spend the treatment nights in randomized order under polysomnographic surveillance, including transcutaneous PCO2 measurement.

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: NIV
Description: Patients with COPD and chronic hypercapnic respiratory failure will spent two nights on NIV, one with spontaneous timed pressure controlled bilevel ventilation (BiPAP ST) and one with the advanced mode of intelligent volume assured pressure support (IVAPS). Patients will spend the treatment nights in randomized order under polysomnographic surveillance, including transcutaneous PCO2 measurement.
Study: NCT00411359

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Cardiac rehabilitation
Description: Phase III cardiac rehabilitation programme
Study: NCT02874456

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: virus detection
Description: Men will give semen, urine and blood specimens 7 days after the beginning of clinical signs and 11, 20, 30, 60 and 90 days after. ZIKV RNA will be detected in seminal plasma, native semen cells and processed spermatozoa.
Study: NCT02043548

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: tocilizumab
Description: given at a dose of 8mg/kg by IV infusion every 4 weeks at 6 time points (Visits 1, 2, 3, 4, 5 and 6).

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: placebo
Description: given by IV infusion every 4 weeks at 6 time points (Visits 1, 2, 3, 4, 5 and 6).
Study: NCT01483781

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Canagliflozin
Description: Type = exact number, unit = mg, number = 300, form = capsule, route = oral use. One encapsulated tablet once daily for up to approximately 85 days (approximately 12 weeks)

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Form = capsules, route = oral use. One capsule once daily for up to approximately 85 days (approximately 12 weeks)
Study: NCT02994433

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Nitrous Oxide
Description: Nitrous oxide, an odorless, colorless gas typically used as an induction agent for general anesthesia or for dental sedation, is a known N-methyl-D-aspartate (NMDA) antagonist. It will be given at 50% nitrous oxide/50% oxygen in this study.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo gas
Description: Placebo gas given at 50% nitrogen \[inert\]/50% oxygen.

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: MRI
Description: MRIs done on all participants, this is a tool we are using to measure outcomes. No treatment is from an MRI.

Intervention type: DEVICE
Group type: PLACEBO_COMPARATOR
Intervention: MRI
Description: MRIs done on all participants, this is a tool we are using to measure outcomes. No treatment is from an MRI.
Study: NCT04519411

Intervention type: DIAGNOSTIC_TEST
Group type: EXPERIMENTAL
Intervention: Transpulmonary pressure measurements
Description: Transpulmonary pressure measurements
Study: NCT03209206

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Docetaxel
Description: Intravesical Instillation of Docetaxel (Docetaxel 75 mg diluted in 100 cc of normal saline) after operation of Upper urinary tract urothelial carcinoma (With in 48 hrs)

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo Normal saline
Description: Intravesical Instillation of Normal saline (100 cc of normal saline) after operation of Upper urinary tract urothelial carcinoma (With in 48 hrs)
Study: NCT02947152

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: HKT288
Description: Cadherin-6-targeting antibody-drug conjugate for intravenous administration

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: HKT288
Description: Cadherin-6-targeting antibody-drug conjugate for intravenous administration

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: HKT288
Description: Cadherin-6-targeting antibody-drug conjugate for intravenous administration
Study: NCT02346032

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: refametinib
Description: Refametinib will be administered orally at the starting dose of 50 mg twice daily on a continuous daily dosing schedule.
Study: NCT01223170

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Tailored content
Description: Participants will have access to content tailored for Stage of Change, Regulatory Focus and Self-Efficacy.

Intervention type: BEHAVIORAL
Group type: PLACEBO_COMPARATOR
Intervention: Generic Internet-based information
Description: Access to a website with general information about Cardiovascular Disease and self-management, including diet, physical activity, smoking and medications.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Generic Internet-based information
Description: Access to a website with general information about Cardiovascular Disease and self-management, including diet, physical activity, smoking and medications.

Intervention type: BEHAVIORAL
Group type: PLACEBO_COMPARATOR
Intervention: Discussion forum
Description: Access to a discussion forum for Cardiovascular Disease Rehabilitation.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Discussion forum
Description: Access to a discussion forum for Cardiovascular Disease Rehabilitation.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Behavioral monitoring
Description: Participants will be offered behavioral monitoring, based on data collected from online self-reports and from activity sensors built into mobile phones.
Study: NCT00254748

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Quetiapine fumarate
Description: flexible doses from 200 mg to 600 mg

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: placebo
Study: NCT02716051

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: MRI
Description: Whole body MRI with cardiac and pulmonary synchronization

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: PET
Study: NCT02993874

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Creatine
Description: The experimental group will ingest for seven days (Loading - phase 1), 5g (4x/day) of creatine monohydrate associated with the clinical treatment (30-45 minutes of walking, 3 times a week). Subsequently, they will ingest for 49 days (Maintenance - phase 2), 3g (1x / day) creatine monohydrate associated with clinical treatment (30-45 minutes of walking, 3 times a week). They will be given guidance by telephone, so that they can reach the necessary recommendations for the study.

Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: The placebo group will ingest for seven days (Loading - phase 1), 5g (4x / day) of dextrose associated to clinical treatment (30-45 minutes of walking, 3 times per week). Subsequently, they will ingest for 49 days (Maintenance phase 2), 3g (1x / day) of dextrose associated with the clinical treatment (30-45 minutes of walking, 3 times a week). They will be given guidance by telephone, so that they can reach the necessary recommendations for the study.
Study: NCT02100436

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Influenza Virus Vaccine, Monovalent A/H3N2v A/Minnesota/11/2010 NYMC X-203
Description: A unadjuvanted subvirion monovalent inactivated split influenza virus vaccine (H3N2v MIV) produced in eggs. Subjects are enrolled in 3 cohorts stratified by age. 6-35 month old subjects receive 2 doses of H3N2v MIV, intramuscularly (IM) as 7.5 micrograms (mcg) of hemagglutinin (HA)/0.25 milliliter (mL) dose, 21 days apart, or 2 doses of H3N2v MIV, IM as 15mcg HA/0.5mL dose, 21 days apart. 3-8 year old subjects and 9-17 year old subjects receive 2 doses of H3N2v MIV, IM as 15mcg HA/0.5mL dose, 21 days apart.

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Influenza Virus Vaccine, Monovalent A/H3N2v A/Minnesota/11/2010 NYMC X-203
Description: A unadjuvanted subvirion monovalent inactivated split influenza virus vaccine (H3N2v MIV) produced in eggs. Subjects are enrolled in 3 cohorts stratified by age. 6-35 month old subjects receive 2 doses of H3N2v MIV, intramuscularly (IM) as 7.5 micrograms (mcg) of hemagglutinin (HA)/0.25 milliliter (mL) dose, 21 days apart, or 2 doses of H3N2v MIV, IM as 15mcg HA/0.5mL dose, 21 days apart. 3-8 year old subjects and 9-17 year old subjects receive 2 doses of H3N2v MIV, IM as 15mcg HA/0.5mL dose, 21 days apart.

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Influenza Virus Vaccine, Monovalent A/H3N2v A/Minnesota/11/2010 NYMC X-203
Description: A unadjuvanted subvirion monovalent inactivated split influenza virus vaccine (H3N2v MIV) produced in eggs. Subjects are enrolled in 3 cohorts stratified by age. 6-35 month old subjects receive 2 doses of H3N2v MIV, intramuscularly (IM) as 7.5 micrograms (mcg) of hemagglutinin (HA)/0.25 milliliter (mL) dose, 21 days apart, or 2 doses of H3N2v MIV, IM as 15mcg HA/0.5mL dose, 21 days apart. 3-8 year old subjects and 9-17 year old subjects receive 2 doses of H3N2v MIV, IM as 15mcg HA/0.5mL dose, 21 days apart.
Study: NCT00150826

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Quinapril
Description: Quinapril will be started at 40mg daily and titrated to 80mg daily for 16 weeks.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo will be given in a capsule form once daily for 16 weeks.
Study: NCT01392677

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: dapagliflozin
Description: 10 mg tablet, oral, once daily, 24- week treatment and 28- week extension period

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: placebo
Description: matching placebo tablet, oral, once daily, 24- week treatment and 28- week extension period
Study: NCT02589691

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Rocuronium

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Sodium chloride 0.9%
Study: NCT03402984

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Acotiamide
Description: Acotiamide treatment, 100 mg, t.i.d. for three week. Intake 10 minutes before meal.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo Oral Tablet
Description: Placebo treatment, t.i.d. for three week. Intake 10 minutes before meal.
Study: NCT02781909

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ibuprofen
Description: Non-Steroid Anti-Inflammatory drug to be administered as adjunctive therapy

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Standard of Care TB treatment
Description: Standard of Care (SoC) TB Treatment will be optimized and drugs selected according to the National and WHO Guidelines, sensitivity profile and as per routine.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Standard of Care TB treatment
Description: Standard of Care (SoC) TB Treatment will be optimized and drugs selected according to the National and WHO Guidelines, sensitivity profile and as per routine.
Study: NCT04232228

Intervention type: OTHER
Intervention: No intervention
Description: No intervention was used in this study.
Study: NCT04127253

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Sooma transcranial direct current stimulation device plus Brain training tools
Description: This group will carry out an observation training of actions and motor imagery in combination with the stimulation of the transcranial direct current.

Intervention type: DEVICE
Group type: PLACEBO_COMPARATOR
Intervention: Placebo Sooma transcranial direct current stimulation deviceplus Brain training tools
Description: This group will carry out an observation training of actions and motor imagery in combination with the placebo stimulation of the transcranial direct current, where it will be acrtivo during 15 seconds and then it will be turned off during the rest of the intervention.

Intervention type: BEHAVIORAL
Group type: SHAM_COMPARATOR
Intervention: Brain training tools in isolation
Description: This group will act as a control, they will only carry out the training of action observation and motor imagery.
Study: NCT02404623

Intervention type: DIETARY_SUPPLEMENT
Group type: OTHER
Intervention: Vitamin D
Description: also known as Cholecalciferol, is one of the two most important compounds within the group of Vitamin D. It can be ingested from the diet and from supplements. In this study it is pharmacologically acquired and referred to as Vitamin D

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Vitamin D
Description: also known as Cholecalciferol, is one of the two most important compounds within the group of Vitamin D. It can be ingested from the diet and from supplements. In this study it is pharmacologically acquired and referred to as Vitamin D
Study: NCT02858908

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Tideglusib
Description: Tideglusib for oral suspension,

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Tideglusib
Description: Tideglusib for oral suspension,
Study: NCT04563494

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: dexamethasone
Description: Prevention of post op nausea and vomiting

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: dexamethasone
Description: Prevention of post op nausea and vomiting
Study: NCT03853239

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: face mask ventilation crossover nasal ventilation
Description: Group A was first ventilated through the face mask, and the tidal volume was measured under pressure-controlled mode (10, 15, 20 cm H2O) ;Switched to volume-controlled (6,8,10ml/kg predicted body weight)mode, the actual tidal volume was recorded, and the air leakage was calculated. Then, put a nasal RAE tube in one side of the nostril, inflate the cuff, make the catheter in a natural position after inflation, clip the other side of the nostril, close the lip with tape, connect the breathing circuit, record the actual tidal volume; measure the expired tidal volume during pressure-controlled ventilation (10, 15, 20 cm H2O).Subject will start with one technique and then cross over to the other technique.

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: nasal ventilation crossover face mask ventilation
Description: Group B first placed a nasal RAE tube in one side of the nostril, the cuff was inflated, the catheter was in a natural position after inflation, the other side of the nostril was clamped, the lip was closed with tape, the breathing circuit was connected, and the amount of tidal volume was measured under pressure-controlled mode ( 10,15,20cm H2O) ; switch to volume-controlled ventilation mode (6,8,10ml/kg predicted body weight), record the actual tidal volume; pull out the tracheal tube, perform mask ventilation, record the actual tidal volume and tidal volume under volume-controlled mode(6,8,10ml/kg predicted body weight) and pressure-controlled mode (10, 15, 20 cm H2O) , respectively.Subject will start with one technique and then cross over to the other technique.
Study: NCT04719143

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Cognitive Behavioral Therapy for Insomnia (CBT-I)
Description: Subjects receive 6-8 CBT-I sessions in an individual format.
Study: NCT01326182

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: MAADRE
Description: Group-based intervention combining asthma education and CBT for depressive symptoms

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: MAAS
Description: Group-based intervention including asthma education and education regarding general child health
Study: NCT01791348

Intervention type: OTHER
Group type: OTHER
Intervention: d2 test of attention
Study: NCT04540146

Intervention type: DIAGNOSTIC_TEST
Intervention: Flow-Cytometric analysis
Description: IL-2, 4, 5, 6, 9, 10, 13, 17A, 17F, 22, IFN-γ and TNF-α levels in the intraabdominal ascites

Intervention type: DIAGNOSTIC_TEST
Intervention: Flow-Cytometric analysis
Description: IL-2, 4, 5, 6, 9, 10, 13, 17A, 17F, 22, IFN-γ and TNF-α levels in the intraabdominal ascites
Study: NCT04492462

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Formal Physical Therapy
Description: Patients will undergo standard physical therapy following their surgery with a physical therapist in an office

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Self-directed Physical Therapy
Description: Patients will undergo self-directed physical therapy in the comfort of their own home by completing a list of exercises and stretches without the direct supervision of a physical therapist in a physical therapist office
Study: NCT01969487

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Preoperative warm-up on simulator
Study: NCT02670824

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: CN-105
Description: Single and multiple intravenous (IV) doses of CN-105

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Normal Saline
Study: NCT00683163

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: PTH(1-84)
Description: 1.4 mg injected subcutaneously (in the abdomen) daily

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: PTH(1-84)
Description: 1.4 mg injected subcutaneously (in the abdomen) daily

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Ibandronate
Description: 150mg by mouth once monthly

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Ibandronate
Description: 150mg by mouth once monthly

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Placebo injection
Description: Daily injections as placebo for PTS 1-84

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Placebo injection
Description: Daily injections as placebo for PTS 1-84

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Placebo pills
Description: Monthly pills as placebo for oral ibandronate
Study: NCT02596477

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Vepoloxamer

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Vepoloxamer

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: 5% dextrose in water
Study: NCT01724840

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: GraftJacket
Description: Interposition with GraftJacket

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Tendon Interposition
Description: Tendon Interposition with the FCR tendon
Study: NCT02322125

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: ReWalk
Description: Intensive training with the ReWalk to negotiate smooth ground, rough terrain indoors and outdoors, ascending and descending slopes and steps, in a home setting and in the community.
Study: NCT01199588

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Nexagon® Low Dose
Description: Weekly, topical application of Nexagon® low dose used with compression dressings.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Nexagon® High Dose
Description: Weekly, topical application of Nexagon® high dose used with compression dressings.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Nexagon® Vehicle
Description: Weekly, topical application of Nexagon® Vehicle used with compression dressings.
Study: NCT00257166

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ziprasidone oral capsules
Description: Oral ziprasidone capsules of 20 mg, 40 mg, 60 mg, and 80 mg strength administered BID.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: placebo oral capsules
Description: Oral placebo capsules of 20 mg, 40 mg, 60 mg, and 80 mg strength administered BID.
Study: NCT01887236

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Step physical activity program
Description: Participants will take part in a biweekly, 8 week physical activity program that will include step exercises

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Stability Ball Program
Description: Participants will take part in a biweekly, 8 week physical activity program that will include stability ball exercises
Study: NCT02768337

Intervention type: DRUG
Group type: OTHER
Intervention: Afatinib

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Afatinib

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Afatinib

Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: 2 Gy targeted radiotherapy

Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: 4 Gy targeted radiotherapy
Study: NCT02280395

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: RUT058-60
Description: Prior to closure of the abdomen at the end of the surgical repair, each subject will undergo lavage with approximately 900 mL of RUT058-60 administered as two 400 mL intra-abdominal (peritoneal) lavages and one 100 mL lavage above the fascia.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Sterile saline for irrigation
Description: Prior to closure of the abdomen, each subject will undergo lavage with approximately 900 mL of sterile saline administered as two 400 mL intra-abdominal (peritoneal) lavages and one 100 mL lavage above the fascia.